drugset / Trial / NCT02739373

Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects

NCT02739373 ↗

Phase 1 Completed 76 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The main purpose of this study is to measure the amount of study drug (BMS-986189) in the blood and urine and to see if BMS-986189 is safe and well-tolerated in healthy people after a single dose.

Timeline

Start
2016-04-18
Primary completion
2016-12-14
Completion
2016-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986189 Unknown — —